Epidemiologic Study of Inflammatory Bowel Disease; Notice of Intent To Fund Single Eligibility Award, 48134-48135 [05-16172]
Download as PDF
<![CDATA[
48134
Federal Register / Vol. 70, No. 157 / Tuesday, August 16, 2005 / Notices
collection of information is accurate,
and based on valid assumptions and
methodology; ways to enhance the
quality, utility, and clarity of the
information to be collected.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DATES:
Submit comments on or before:
September 15, 2005.
[Program Announcement DP05–130]
FOR FURTHER INFORMATION CONTACT:
Linda Nelson, Procurement Analyst,
Contract Policy Division, at telephone
(202) 501–1900 or via email at
linda.nelson@gsa.gov.
Epidemiologic Study of Inflammatory
Bowel Disease; Notice of Intent To
Fund Single Eligibility Award
A. Purpose
Centers for Disease Control and
Prevention
Submit comments regarding
this burden estimate or any other aspect
of this collection of information,
including suggestions for reducing this
burden to Ms. Jeanette Thornton, GSA
Desk Officer, OMB, Room 10236, NEOB,
Washington, DC 20503, and a copy to
the Regulatory Secretariat (VIR), General
Services Administration, Room 4035,
1800 F Street, NW., Washington, DC
20405. Please cite OMB Control No.
3090–0262, Identification of Products
with Environmental Attributes, in all
correspondence.
ADDRESSES:
SUPPLEMENTARY INFORMATION:
A. Purpose
B. Eligible Applicant
General Services Administration
(GSA) requires contractors submitting
Multiple Award Schedule Contracts to
identify in their GSA price lists those
products that they market commercially
that have environmental attributes. The
identification of these products will
enable Federal agencies to maximize the
use of these products to meet the
responsibilities expressed in statutes
and executive orders.
B. Annual Reporting Burden
Respondents: 16,941.
Responses Per Respondent: 1.
Annual Responses: 16,941.
Hours Per Response: 5.
Total Burden Hours: 84,705.
Obtaining Copies of Proposals:
Requesters may obtain a copy of the
information collection documents from
the General Services Administration,
Regulatory Secretariat (VIR), 1800 F
Street, NW., Room 4035, Washington,
DC 20405, telephone (202) 208–7312.
Please cite OMB Control No. 3090–0262,
Identification of Products with
Environmental Attributes, in all
correspondence.
Dated: August 11, 2005.
Gerald Zaffos,
Acting Director, Contract Policy Division.
[FR Doc. 05–16208 Filed 8–15–05; 8:45 am]
BILLING CODE 6820–61–S
VerDate jul<14>2003
The Centers for Disease Control and
Prevention (CDC) announces the intent
to fund fiscal year (FY) 2005 funds for
a cooperative agreement program to
expand on preliminary findings of
Inflammatory Bowel Disease (IBD) in
the United States and enhance our
understanding of the demographic and
clinical characteristics of IBD, variations
in clinical practice, and the impact of
the disease. This announcement will
build on a previous epidemiologic study
of the disease and be used to target
interventions for groups at high risk for
IBD and inform best clinical practices.
The Catalog of Federal Domestic
Assistance number for this program is
93.945.
18:02 Aug 15, 2005
Jkt 205001
Assistance will be provided only to
the Crohn’s and Colitis Foundation of
America.
The Crohn’s and Colitis Foundation of
America is the only institution eligible
to submit an application in response to
this RFA. The CCFA was referenced by
the House and Senate in their Labor/
Health and Human Services/Education
(L/HHS/Ed) Committee Reports. The
House language states: ‘‘For the past five
years, the Committee has encouraged
CDC to work in partnership with the
IBD community to establish a national
IBD epidemiology program to further
our understanding of these diseases.
The Committee understands that the
Crohn’s and Colitis Foundation of
America has provided financial support
through the CDC Foundation to initiate
this important program. Now that the
project is established, the Committee
encourages CDC to contribute to the
project in order to expand the work in
FY2005.’’ The Senate language states:
‘‘An epidemiological study of IBD is
needed to gain a better understanding of
the prevalence of IBD in the United
States and the demographic
characteristics of the IBD patient
population. Over the last 3 years, the
Crohn’s and Colitis Foundation of
America has provided the CDC with
$750,000 to initiate the epidemiological
study. Now that the project has been
established through an investment by
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
the patient community, the Committee
has provided $800,000 to continue this
study.’’ The Conference Committee
recommended a total of $750,000.
The CCFA is a not-for-profit 501
(c)(03) organization, founded in 1967
‘‘to cure and prevent Crohn’s disease
and ulcerative colitis through research,
and to improve the quality of life of
children and adults affected by these
digestive disease through education and
support’’. Since 1967, CCFA has
established itself as the leading agency
in the country on IBD research. It has
led the efforts in identifying the
research needs and developing
successful strategies to meet those
needs. CCFA has a national scientific
advisory committee comprised of
nationally renowned physicians and
scientists in the field of inflammatory
bowel disease. This advisory committee
is the only one of its kind in the country
dedicated solely to identifying and
supporting emerging areas of research
that could lead to the understanding of
the causes and disease course of IBD.
Through this scientific advisory
committee and other partnerships,
CCFA has developed several major
initiatives to advance IBD research.
For the past three years, the CCFA
scientific advisory committee has
worked with the CDC to establish the
informational infrastructure needed to
conduct IBD research. They have built
a validated disease algorithm for
identifying patients with IBD and
estimating the prevalence of the disease.
Only CCFA has access to these
algorithms and the informational
infrastructure. CCFA will use the
algorithms and infrastructure created, to
further describe the prevalence and
incidence of IBD and the impact of
various clinical practices on outcomes.
The mission of CCFA, the
organization’s extensive network of
resources, and the existing collaborative
efforts with the CDC make it highly
probable that CCFA will successfully
achieve the activities identified in
Section 1 of this RFA. CCFA is the only
not-for-profit national IBD organization
that promotes and provides funding for
much needed IBD research. This
characteristic of CCFA is unmatched by
any other public or private IBD specific
organization currently conducting
similar activities in the United States.
The CCFA has partnered with the
CDC in the establishment and initiation
of this study; therefore, it is the only
eligible organization to collaborate in
the completion of this study.
C. Funding
Approximately $700,000 is available
in FY 2005 to fund this award. It is
E:\FR\FM\16AUN1.SGM
16AUN1
Federal Register / Vol. 70, No. 157 / Tuesday, August 16, 2005 / Notices
expected that the award will begin on or
before August 31, 2005, and will be
made for a 12-month budget period
within a project period of up to five
years. Funding estimates may change.
D. Where To Obtain Additional
Information
For general comments or questions
about this announcement, contact:
Technical Information Management,
CDC Procurement and Grants Office,
2920 Brandywine Road, Atlanta, GA
30341–4146, telephone: 770–488–2700.
For technical questions about this
program, contact: Brenda Colley Gilbert,
Project Officer, 4770 Buford Highway
N.E., Mailstop K–92, Atlanta, GA 30341,
telephone: 770–488–8390, e-mail:
BColleyGilbert@cdc.gov.
Dated: August 10, 2005.
Alan A. Kotch,
Deputy Director, Procurement and Grants
Office, Centers for Disease Control and
Prevention.
[FR Doc. 05–16172 Filed 8–15–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Program Announcement AA226]
Provider Education and Public
Awareness About Primary
Immunodeficiency Disease; Notice of
Intent To Fund Single Eligibility Award
A. Purpose
The Centers for Disease Control and
Prevention (CDC) announces the intent
to fund fiscal year (FY) 2005 funds for
a grant program to the Jeffrey Modell
Foundation for a National Campaign for
Provider Education and Public
Awareness about Primary
Immunodeficiency (PI Disease). The
purpose of the program is to strengthen
the nation’s capacity to carry out public
health activities in the area of PI
diseases by increasing physician
education and public health awareness
through the program for primary
immune deficiency disease as
implemented by the Jeffrey Modell
Foundation. The objective is to
disseminate educational information on
a national level to public and private
health care providers, educators, thirdparty payers, impacted families, and
others who may help expedite clinical
recognition and improve the health
outcome for Americans with PI disease.
The Catalog of Federal Domestic
VerDate jul<14>2003
18:02 Aug 15, 2005
Jkt 205001
Assistance number for this program is
93.283.
B. Eligible Applicant
Assistance will be provided only to
the Jeffrey Modell Foundation (JMF) in
accordance with language in the
Conference Report to the fiscal year
2005 Appropriations (Pub. L. 108–447,
H.R. Rep. No. 108–792 2004)which
explains congressional intent that CDC
continue to provide funding to JMF. The
specific language is as follows:
‘‘In each of last three years, Congress has
made available funds for CDC to support the
national physician education and public
awareness campaign developed by the Jeffrey
Modell Foundation. The Committee
understands that the Foundation has
leveraged more than seven dollars from
donors and the media for every federal dollar
appropriated and is a model of public-private
cooperation. The Committee encourages the
CDC to expand the reach of the Foundation’s
campaign to underserved communities,
including African-American and Hispanic
populations, and has provided sufficient
funding to reach that critical goal. The
Committee also encourages CDC to expand
its programmatic activity on primary immune
deficiency diseases to include pilot programs
focused on newborn screening and school
wellness.’’
The Jeffrey Modell Foundation, Inc.
(JMF) was established in 1987 to
address early and precise diagnosis,
meaningful treatments, and ultimately
cures for Primary Immunodeficiency
Diseases in memory of Jeffrey Modell,
who died from pneumonia due to
Primary Immunodeficiency at the age of
15. It is a multi-faceted nonprofit
research foundation devoted to the early
and precise diagnosis, meaningful
treatment, and ultimate cure of PI. The
Jeffrey Modell Foundation is focused on
the following Primary
Immunodeficiency treatment,
education, awareness and research
areas: Clinical and basic research to
better understand and treat Primary
Immunodeficiencies; function as a
national and international source for the
dissemination of information and
education into the diagnosis and
treatment of genetic
immunodeficiencies; advocates on
behalf of patients and families to assure
access to excellent and comprehensive
care; promote awareness of Primary
Immunodeficiency diseases through
programs involving lay, scientific, and
medical communities; and addressing
quality of life concerns for patients with
Primary Immunodeficiency diseases.
The activities that are conducted to
achieve the above objectives and focuses
consist of but are not limited to the
following: Sponsored symposiums and
workshops; support for research and
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
48135
training; and the provision of
diagnostic, clinical, and education
services. The Foundation supports a 24hour-a-day national hotline, which
offers information and referrals to
immunologists at major medical centers
around the country. We are not aware of
another organization with a similar
background, approach, and as broad a
reach in the spectrum of issues related
to Primary Immunodeficiency diseases
such as the international focus, service
delivery, and quality of life for PI
patients and their families, and the
other areas referenced above.
No other applications are solicited.
C. Funding
Approximately $2,458,778 is available
in FY 2005 to fund this award. It is
expected that the award will begin on or
before August 31, 2005, and will be
made for a 12-month budget period
within a project period of up to five
years. Funding estimates may change.
D. Where To Obtain Additional
Information
For general comments or questions
about this announcement, contact:
Technical Information Management,
CDC Procurement and Grants Office,
2920 Brandywine Road, Atlanta, GA
30341–4146, telephone: (770) 488–2700.
For technical questions about this
program, contact: Leah Simpson,
M.B.A., Project Officer, 2877
Brandywine Road, Suite 4847, Atlanta,
GA 30341, telephone: (770) 488–8395, email: LSimpson@cdc.gov.
Dated: August 10, 2005.
Alan A. Kotch,
Deputy Director, Procurement and Grants
Office, Centers for Disease Control and
Prevention.
[FR Doc. 05–16169 Filed 8–15–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Strengthening Non-Governmental
Organizations (NGOs) and PrivateSector Care Networks in the Republic
of India as Part of the President’s
Emergency Plan for AIDS Relief
Announcement Type: New.
Funding Opportunity Number: CDC–
RFA–AA058.
Catalog of Federal Domestic
Assistance Number: 93.067.
Key Dates: Application Deadline:
September 9, 2005.
E:\FR\FM\16AUN1.SGM
16AUN1
]]>Agencies
[Federal Register Volume 70, Number 157 (Tuesday, August 16, 2005)]
[Notices]
[Pages 48134-48135]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-16172]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Program Announcement DP05-130]
Epidemiologic Study of Inflammatory Bowel Disease; Notice of
Intent To Fund Single Eligibility Award
A. Purpose
The Centers for Disease Control and Prevention (CDC) announces the
intent to fund fiscal year (FY) 2005 funds for a cooperative agreement
program to expand on preliminary findings of Inflammatory Bowel Disease
(IBD) in the United States and enhance our understanding of the
demographic and clinical characteristics of IBD, variations in clinical
practice, and the impact of the disease. This announcement will build
on a previous epidemiologic study of the disease and be used to target
interventions for groups at high risk for IBD and inform best clinical
practices.
The Catalog of Federal Domestic Assistance number for this program
is 93.945.
B. Eligible Applicant
Assistance will be provided only to the Crohn's and Colitis
Foundation of America.
The Crohn's and Colitis Foundation of America is the only
institution eligible to submit an application in response to this RFA.
The CCFA was referenced by the House and Senate in their Labor/Health
and Human Services/Education (L/HHS/Ed) Committee Reports. The House
language states: ``For the past five years, the Committee has
encouraged CDC to work in partnership with the IBD community to
establish a national IBD epidemiology program to further our
understanding of these diseases. The Committee understands that the
Crohn's and Colitis Foundation of America has provided financial
support through the CDC Foundation to initiate this important program.
Now that the project is established, the Committee encourages CDC to
contribute to the project in order to expand the work in FY2005.'' The
Senate language states: ``An epidemiological study of IBD is needed to
gain a better understanding of the prevalence of IBD in the United
States and the demographic characteristics of the IBD patient
population. Over the last 3 years, the Crohn's and Colitis Foundation
of America has provided the CDC with $750,000 to initiate the
epidemiological study. Now that the project has been established
through an investment by the patient community, the Committee has
provided $800,000 to continue this study.'' The Conference Committee
recommended a total of $750,000.
The CCFA is a not-for-profit 501 (c)(03) organization, founded in
1967 ``to cure and prevent Crohn's disease and ulcerative colitis
through research, and to improve the quality of life of children and
adults affected by these digestive disease through education and
support''. Since 1967, CCFA has established itself as the leading
agency in the country on IBD research. It has led the efforts in
identifying the research needs and developing successful strategies to
meet those needs. CCFA has a national scientific advisory committee
comprised of nationally renowned physicians and scientists in the field
of inflammatory bowel disease. This advisory committee is the only one
of its kind in the country dedicated solely to identifying and
supporting emerging areas of research that could lead to the
understanding of the causes and disease course of IBD. Through this
scientific advisory committee and other partnerships, CCFA has
developed several major initiatives to advance IBD research.
For the past three years, the CCFA scientific advisory committee
has worked with the CDC to establish the informational infrastructure
needed to conduct IBD research. They have built a validated disease
algorithm for identifying patients with IBD and estimating the
prevalence of the disease. Only CCFA has access to these algorithms and
the informational infrastructure. CCFA will use the algorithms and
infrastructure created, to further describe the prevalence and
incidence of IBD and the impact of various clinical practices on
outcomes.
The mission of CCFA, the organization's extensive network of
resources, and the existing collaborative efforts with the CDC make it
highly probable that CCFA will successfully achieve the activities
identified in Section 1 of this RFA. CCFA is the only not-for-profit
national IBD organization that promotes and provides funding for much
needed IBD research. This characteristic of CCFA is unmatched by any
other public or private IBD specific organization currently conducting
similar activities in the United States.
The CCFA has partnered with the CDC in the establishment and
initiation of this study; therefore, it is the only eligible
organization to collaborate in the completion of this study.
C. Funding
Approximately $700,000 is available in FY 2005 to fund this award.
It is
[[Page 48135]]
expected that the award will begin on or before August 31, 2005, and
will be made for a 12-month budget period within a project period of up
to five years. Funding estimates may change.
D. Where To Obtain Additional Information
For general comments or questions about this announcement, contact:
Technical Information Management, CDC Procurement and Grants Office,
2920 Brandywine Road, Atlanta, GA 30341-4146, telephone: 770-488-2700.
For technical questions about this program, contact: Brenda Colley
Gilbert, Project Officer, 4770 Buford Highway N.E., Mailstop K-92,
Atlanta, GA 30341, telephone: 770-488-8390, e-mail:
BColleyGilbert@cdc.gov.
Dated: August 10, 2005.
Alan A. Kotch,
Deputy Director, Procurement and Grants Office, Centers for Disease
Control and Prevention.
[FR Doc. 05-16172 Filed 8-15-05; 8:45 am]
BILLING CODE 4163-18-P
